Paul Mahon Net Worth

The estimated Net Worth of Paul A Mahon is at least $32.7 Milion dollars as of 20 June 2024. Mr. Mahon owns over 25,000 units of United Therapeutics Corp stock worth over $21,363,385 and over the last 20 years he sold UTHR stock worth over $3,732,640. In addition, he makes $7,564,550 as Executive Vice President, General Counsel oraz Corporate Secretary at United Therapeutics Corp.

Mr. Mahon UTHR stock SEC Form 4 insiders trading

Paul has made over 394 trades of the United Therapeutics Corp stock since 2004, according to the Form 4 filled with the SEC. Most recently he exercised 25,000 units of UTHR stock worth $4,082,500 on 20 June 2024.

The largest trade he's ever made was exercising 72,000 units of United Therapeutics Corp stock on 2 February 2012 worth over $1,823,040. On average, Paul trades about 5,564 units every 17 days since 2004. As of 20 June 2024 he still owns at least 61,710 units of United Therapeutics Corp stock.

You can see the complete history of Mr. Mahon stock trades at the bottom of the page.

Paul Mahon biography

Paul A. Mahon J.D. serves as Executive Vice President, General Counsel, Corporate Secretary of the Company. He has served as General Counsel and Corporate Secretary of United Therapeutics since its inception in 1996. In June 2001, Mr. Mahon joined United Therapeutics full-time as Senior Vice President, General Counsel and Corporate Secretary. In November 2003, Mr. Mahon was promoted to Executive Vice President, General Counsel and Corporate Secretary. Prior to June 2001, he served United Therapeutics, beginning with its formation in 1996, in his capacity as principal and managing partner of a law firm specializing in technology and media law.

What is the salary of Paul Mahon?

As the Executive Vice President, General Counsel oraz Corporate Secretary of United Therapeutics Corp, the total compensation of Paul Mahon at United Therapeutics Corp is $7,564,550. There are 2 executives at United Therapeutics Corp getting paid more, with Martine Rothblatt having the highest compensation of $15,627,500.

How old is Paul Mahon?

Paul Mahon is 56, he's been the Executive Vice President, General Counsel oraz Corporate Secretary of United Therapeutics Corp since 2003. There are 14 older and 5 younger executives at United Therapeutics Corp. The oldest executive at United Therapeutics Corp is Louis Sullivan, 86, who is the Independent Director.

What's Paul Mahon's mailing address?

Paul's mailing address filed with the SEC is C/O UNITED THERAPEUTICS CORPORATION, 1000 SPRING STREET, SILVER SPRING, MD, 20910.

Insiders trading at United Therapeutics Corp

Over the last 20 years, insiders at United Therapeutics Corp have traded over $68,910,395 worth of United Therapeutics Corp stock and bought 229,703 units worth $13,655,671 . The most active insiders traders include Martine A Rothblatt, David Zaccardelli oraz Roger Jeffs. On average, United Therapeutics Corp executives and independent directors trade stock every 3 days with the average trade being worth of $2,310,818. The most recent stock trade was executed by James Edgemond on 9 September 2024, trading 8,332 units of UTHR stock currently worth $991,341.

What does United Therapeutics Corp do?

united therapeutics corporation is a biotechnology company focused on the development and commercialization of unique products to address the unmet medical needs of patients with chronic and life-threatening conditions. we currently have five approved products on the market, and a long-term mission of providing an unlimited supply of transplantable organs for those who need them! our employees can be found collaborating across the united states, europe and asia. as a group, we are relentless in our pursuit of “medicines for life” and continue to research and develop treatments for cardiovascular and pulmonary diseases, pediatric cancers, and other orphan diseases. #weareunitherians

Complete history of Mr. Mahon stock trades at United Therapeutics Corp

United Therapeutics Corp executives and stock owners

United Therapeutics Corp executives and other stock owners filed with the SEC include:

• Martine Rothblatt,
  Chairman of the Board, Chief Executive Officer
• Michael Benkowitz,
  President, Chief Operating Officer
• Paul Mahon,
  Executive Vice President, General Counsel, Corporate Secretary
• James Edgemond,
  Chief Financial Officer, Treasurer
• Dr. Martine A. Rothblatt J.D., M.B.A., Ph.D.,
  Founder, Chairman & CEO
• Dr. Martine A. Rothblatt,
  Founder, Chairman & CEO
• Michael I. Benkowitz,
  Pres & COO
• Paul A. Mahon,
  Exec. VP, Gen. Counsel & Corp. Sec.
• Paul A. Mahon J.D.,
  Exec. VP, Gen. Counsel & Corp. Sec.
• James C. Edgemond,
  CFO & Treasurer
• Christopher Patusky,
  Lead Independent Vice Chairman of the Board
• Christopher Causey,
  Independent Director
• Richard Giltner,
  Independent Director
• Louis Sullivan,
  Independent Director
• Tommy Thompson,
  Independent Director
• Nilda Mesa,
  Independent Director
• Judy Olian,
  Independent Director
• Katherine Klein,
  Independent Director
• Raymond Kurzweil,
  Independent Director
• Raymond Dwek,
  Independent Director
• Linda Maxwell,
  Director
• Dewey Steadman C.F.A.,
  Head of Investor Relations
• Leigh Peterson,
  VP of Product Devel.
• Gil Golden,
  Sr. VP & Chief Medical Officer
• Patrick Poisson,
  Exec. VP of Technical Operations
• Kevin T. Gray,
  Sr. VP of Strategic Operations & Logistics
• Holly Hobson,
  Associate VP of HR
• Dewey Steadman C.F.A., CFA,
  Head of Investor Relations
• Jan Malcolm,
  
• Ray Kurzweil,
  
• Roger Jeffs,
  President & COO
• Fred T Hadeed,
  EVP & CFO
• David Zaccardelli,
  EVP & Chief Operating Officer
• John Maxim Ferrari,
  CFO & Treasurer
• R Paul Gray,
  Director
• Lilly & Co Eli,
  Director, Chairman and CEO